In Trusts We Trust: Controlling When Your Kids Get Your Money
Break's Over, Santa: Ticketmaster Kicks Off Christmas Season in May
Consumer Spending Forecast to Boost U.S. Economy
Market Minute: Scrutiny Awaits Heads of JPMorgan, Apple
NASDAQ: CORT
Wider-than-Expected Loss at Corcept - Analyst Blog
UPDATE: Piper Jaffray Downgrades Corcept Therapeutics to Neutral Following 1Q13 Earnings Report
Corcept Therapeutics' CEO Discusses Q1 2013 Results - Earnings Call Transcript
2 High Risk Biotech Stocks Under $2 That Could Yield A High Reward
Corcept's Loss Narrows in 4Q - Analyst Blog
2 $2 Biotech Stocks Insiders Are Buying
Corcept Provides 4Q & 2012 Outlook - Analyst Blog
Corcept Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
5 Stocks Setting Up to Break Out
3 Small Cap Movers With Similar Trends But Different Outlooks